- Market Capitalization, $K 127,836,016
- Shares Outstanding, K 2,517,944
- Annual Sales, $ 42,687 M
- Annual Income, $ 14,066 M
- 60-Month Beta 0.57
- Price/Sales 3.08
- Price/Cash Flow 10.01
- Price/Book 1.75
|Period||Period Low||Period High||Performance|
| || |
+2.21 (+4.60%)since 03/12/21
| || |
+2.18 (+4.54%)since 01/13/21
| || |
+5.84 (+13.16%)since 04/13/20
Sanofi's (SNY) acquisition of Tidal Therapeutics for $160 million is set to aid innovative mRNA-based research platform with applications in oncology, immunology and other diseases.
, /PRNewswire/ -- In an , Sanofi Chief Executive Officer today outlined several key projects that the company will implement to increase the impact of its Corporate Social Responsibility (CSR) strategy....
With high hopes for a fast-paced recovery of the U.S. economy, market sentiment is upbeat. However, volatility and inflationary headwinds cannot be ruled out in the near term given the resurgence in COVID-19...
Sanofi's (SNY) Sarclisa gets FDA approval to treat multiple myeloma patients who have received one to three prior lines of therapy in combination with Kyprolis and dexamethasone.
, /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with...
The European Commission approves Novartis' (NVS) Kesimpta for the treatment of adult patients with relapsing forms of multiple sclerosis.
The pharmaceutical industry has a reputation for resilience. Many pharma players that garnered noteworthy momentum amid the COVID-19 pandemic are holding strong even as the pandemic is on a decline. That’s...
J&J's (JNJ) ponesimod demonstrated superior clinical efficacy in reducing annual relapses compared to Sanofi's Aubagio in clinical studies.
Top Analyst Reports for Novo Nordisk, NextEra & 3M Company
Translate Bio (TBIO) announces data from second interim analysis of phase I/II study evaluating MRT5005 in patients with cystic fibrosis. The candidate fails to improve lung function in patients.
|Advisorshares Doubleline Value Equity ETF|
|Pharmaceutical Vaneck ETF|
|Total Intl Stock Ishares Core MSCI ETF|
|Intl Devd Markets Ishares Core MSCI ETF|
|Avantis International Equity ETF|
|3rd Resistance Point||50.95|
|2nd Resistance Point||50.80|
|1st Resistance Point||50.53|
|1st Support Level||50.11|
|2nd Support Level||49.96|
|3rd Support Level||49.69|